Interstitial lung disease: causes, treatment, and prevention

Ethnicity and Disease

Volumn 15, Issue 2 SUPPL. 2, 2005, Pages

  Perez, Rafael L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Anti fibrotic therapy; Granulomatous inflammation; Immunosuppressive therapy; Interstitial lung disease; Pulmonary fibrosis; Restrictive lung impairment

Indexed keywords

EID: 61849179866     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Schwarz MI, King TE Jr, Raghu G. Approach to the evaluation and diagnosis of interstitial lung disease. In: Schwarz MI, King TE Jr, eds. Interstitial Lung Disease. Hamilton, Ontario: B.C. Decker Inc; 2003:1-30.
2. Thomas KW, Hunninghake GW. Sarcoidosis. JAMA. 2003;289(24):3300- 3303.
3. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year srudy in a health maintenance organization. Am J Epidemiol. 1997;145(3):234-241.
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000:161(2):646-664.
5. Lynch DA. Radiologic differential diagnosis of diffuse lung disease. In: Lynch DA, Newell JD Jr, Lee JS, eds. Imaging of Diffuse Lung Disease. Hamilton, Ontario: B.C. Decker Inc; 2000: 35-56.
6. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 ;164(10): 1885-1889.
7. Ziesche R, Hofbauer E, Wittmann K, Perkov V, Block LH. A preliminary srudy of long-term treatment with interferon gamma-lb and low-dose prednisolone in parienrs with idiopathic pulmonary fibrosis. N Engl J Med. 1999; 341(17):1264-1269.